Download Long non-coding RNA (lncRNA) LIPCAR predicts survival in heart

Long non-coding RNA (lncRNA) LIPCAR predicts survival in heart
failure patients
Reference Number: 15-00366
Challenge
Heart Failure (HF) belongs to the major common diseases and occurs in
about 2% of the population worldwide. The primary reasons for HF are
myocardial infarction, hypertension and cardiomyopathy leading to cardiac
remodeling and an insufficient cardiac output. LncRNAs are extracellular
nucleic acids and represent a novel class of regulatory molecules. Recent
studies identified lncRNAs as promising biomarkers for the detection of
various cancers, e.g. prostate cancer. In contrast, the diagnostic potential of
lncRNAs in cardiac diseases is largely unknown.
Technology
Due to dynamically regulation of the myocardial transcriptome in
pathological processes, lncRNAs emerge as new and specific biomarkers for
the diagnosis of cardiovascular diseases. Recent studies identified the
mitochondria-derived lncRNA LIPCAR as a very promising biomarker for the
prognosis of survival in heart failure patients. LIPCAR enables the early
prediction of the future development of cardiac remodeling in patients who
had an episode of myocardial infarction. Further, LIPCAR levels are
associated with future cardiovascular deaths in heart failure patients
independent of other predictors. For this reasons, LIPCAR enables the timely
diagnosis of the disease course and renders possible a therapy of the
patient at an early stage. Thus, LIPCAR is the first available lncRNA
biomarker for the assessment and prognosis of disease progression in heart
failure patients.
Commercial Opportunity
In-licensing or collaboration for further development is possible.
Developmental Status
Studies with blood plasma samples from 800 patients with chronic heart
failure or left ventricular (LV)-remodeling were conducted for identification
and validation of regulated cardiovascular lncRNAs.
Patent Situation
An international PCT application (PCT/EP2015/055713) has been filed with
priority of 2014.
Further Reading
Circulating levels of LIPCAR associated with cardiac
death
Licensing Contact
Dr Torben Söker
Technology Scout
T: +49 511 53289-18
F: +49 511 53289-29
[email protected]
Ascenion GmbH
Herzogstraße 64
D-80803 München
T: +49 89 318814-0
F: +49 89 318814-20
[email protected]
www.ascenion.de
Berlin
Braunschweig
Hamburg
Hanover
Munich
Neuherberg
Kumarswamy R, Bauters C, Volkmann I, Maury F, Fetisch J, Holzmann A,
Lemesle G, de Groote P, Pinet F, Thum T. 2014. Circulating Long Noncoding
RNA, LIPCAR, Predicts Survival in Patients With Heart Failure. Circ Res.
114:1569-1575.
Powered by TCPDF (www.tcpdf.org)